Health CarePharmaceuticals & Biotechnology
  • Price (DKK)376.90
  • Today's Change2.40 / 0.64%
  • Shares traded358.43k
  • 1 Year change24.88%
  • Beta0.9501
Data delayed at least 15 minutes, as of Aug 07 2020 15:59 BST.
More ▼

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

  • Revenue in DKK (TTM)14.68bn
  • Net income in DKK3.27bn
  • Incorporated2000
  • Employees6.07k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NZYM B:CPH since
Precisionbiotics LtdDeal completed25 Jun 202025 Jun 2020Deal completed-0.34%90.00m
Data delayed at least 15 minutes, as of Aug 07 2020 15:59 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Uralkaliy PAO15.45bn6.71bn43.71bn20.50k1.931.165.312.8361.6461.64141.92102.380.31822.857.07--13.818.3818.4811.5475.8676.1843.4126.410.5262--0.7165--3.825.59980.62--11.78--
Arkema SA61.53bn2.99bn51.50bn20.50k17.151.246.680.8375.255.25107.8672.590.78856.076.47402,740.504.035.454.876.7520.1821.565.
Brenntag AG92.44bn3.53bn59.42bn17.23k16.762.3010.250.64273.083.0880.5622.491.477.896.83709,381.405.665.527.617.5622.4421.503.843.491.259.790.420240.
Umicore SA148.04bn1.72bn69.72bn13.74k39.863.5015.770.4710.95270.952782.1710.852.838.1515.251,406,503.003.434.885.518.125.337.361.211.910.87595.520.485942.8727.4716.56-9.2113.0124.87-6.89
Yara International ASA76.94bn2.40bn73.64bn16.03k30.931.478.930.957212.7012.70406.37267.390.72063.626.856,864,
Evonik Industries AG93.76bn4.59bn83.32bn32.47k18.211.277.480.88861.324.0426.9018.880.58884.368.05388,181.202.974.173.615.0527.7331.015.045.961.1113.500.349168.57-1.200.2949.775.47-4.282.83
Novozymes A/S14.68bn3.27bn87.16bn6.07k32.839.8819.505.9411.4811.4851.4838.170.71932.424.962,516,544.0016.0416.3721.4421.1855.7357.4822.3021.520.983838.190.347242.19-0.11122.90-2.234.546.6411.84
Chr Hansen Holding A/S8.84bn1.89bn93.78bn3.42k49.5514.9638.3710.6114.3514.3567.2547.550.55953.006.622,584,411.0011.9512.2814.8614.6955.6954.2221.3520.450.620625.850.539381.535.808.959.6413.6117.3228.68
Akzo Nobel NV64.70bn3.58bn116.90bn33.20k33.392.6517.971.812.442.4643.9730.680.62844.083.71256,952.703.733.915.005.6143.5142.985.946.101.2230.740.328677.820.2161-8.2929.25-0.4202-18.303.10
Data as of Aug 07 2020. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

20.48%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 201914.17m6.13%
MFS International (UK) Ltd.as of 30 Jun 20206.43m2.78%
The Vanguard Group, Inc.as of 30 Jun 20206.06m2.62%
Baillie Gifford & Co.as of 30 Jul 20205.68m2.46%
Harding Loevner LPas of 30 Jun 20202.93m1.27%
Walter Scott & Partners Ltd.as of 29 May 20202.78m1.20%
BlackRock Fund Advisorsas of 09 Jul 20202.67m1.15%
NNIP Advisors BVas of 31 Mar 20202.26m0.98%
Mawer Investment Management Ltd.as of 30 Apr 20202.21m0.96%
Impax Asset Management Ltd.as of 29 May 20202.16m0.93%
More ▼
Data from 31 Dec 2019 - 31 Jul 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.